ROG.VX - Roche Holding AG

Swiss - Swiss Delayed price. Currency in CHF
224.55
+0.55 (+0.25%)
At close: 5:30PM CEST
Stock chart is not supported by your current browser
Previous close224.00
Open224.00
Bid224.00 x 243000
Ask224.50 x 260500
Day's range222.95 - 225.80
52-week range212.45 - 269.50
Volume1,705,087
Avg. volume1,735,625
Market cap192.551B
Beta0.90
PE ratio (TTM)22.37
EPS (TTM)10.04
Earnings date26 Jan 2016 - 1 Feb 2016
Forward dividend & yield8.30 (3.74%)
Ex-dividend date2018-03-15
1y target est259.00
  • Buffett's Berkshire Hathaway halftime show
    Yahoo Finance Video15 days ago

    Buffett's Berkshire Hathaway halftime show

    Yahoo Finance editor-in-chief Andy Serwer, Jen Rogers, Julia La Roche and Myles Udland host the halftime break show at Berkshire Hathaway's annual shareholder meeting in Omaha, Nebraska featuring Warren Buffett and Charlie Munger.

  • Berkshire Hathaway annual shareholder meeting preshow
    Yahoo Finance Video15 days ago

    Berkshire Hathaway annual shareholder meeting preshow

    Berkshire Hathaway is holding its annual shareholder meeting in Omaha, Nebraska. Led by chairman and CEO Warren Buffett and vice chairman Charlie Munger, the meeting has drawn investors, both young and old, seeking wisdom from the investing legends. The event kicks off at 10:15 a.m. ET, and we’ll have the stream live here.

  • Roche CEO 'Very Confident' on European Sales Growth
    Bloomberg Video24 days ago

    Roche CEO 'Very Confident' on European Sales Growth

    Apr.26 -- Severin Schwan, chief executive officer at Roche Holding AG, discusses first-quarter results, the impact of new medicines on European sales and the company's M&A strategy. He speaks with Bloomberg's Nejra Cehic on "Bloomberg Markets: European Open."

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks3 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • The Wall Street Journal4 days ago

    [$$] No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

    The study, funded by the U.K. National Institute for Health Research, was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin, which generated about $7 billion in global sales for Roche last year, has vastly improved treatment for HER2-positive breast cancer since it hit the market in 1998, particularly when used to prevent disease recurrence after breast surgery. In the U.S., the drug costs $76,700 for 12 months of treatment.

  • Study Finds More Isn't Better for Roche Breast Cancer Drug
    Bloomberg4 days ago

    Study Finds More Isn't Better for Roche Breast Cancer Drug

    For more than a decade, women with a dangerous form of breast cancer have relied on Roche Holding AG’s blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. According to research released Wednesday, women taking Herceptin for six months were just as likely to be free of cancer four years later as those who used the drug for a year, the current standard of care recommended by the U.S. Food and Drug Administration and Roche. “Our field is maturing,” said Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston and president of the American Society of Clinical Oncology, or ASCO.

  • Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
    Zacks5 days ago

    Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

    FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

  • Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
    Zacks9 days ago

    Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

    Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.

  • This Biotech Stock Crashed On Colon Cancer Flop With Roche
    Investor's Business Daily10 days ago

    This Biotech Stock Crashed On Colon Cancer Flop With Roche

    Exelixis stock tanked Thursday after a regimen using its drug and another from Roche failed in a late-stage study of hard-to-treat colon cancer patients.

  • Why Exelixis Dropped Today
    Motley Fool10 days ago

    Why Exelixis Dropped Today

    The company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.

  • Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
    Zacks10 days ago

    Inovio's (INO) Q1 Loss Wider than Expected, Shares Down

    Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.

  • Reuters - UK Focus10 days ago

    BUZZ-Top of the Street: IMI, Roche, Beazley, Coloplast

    A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Jefferies upgrades IMI to "buy" on attractive valuation due to recent share price underperformance; broker ...

  • Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
    Zacks11 days ago

    Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

    Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.

  • What's in Store for Prothena (PRTA) This Earnings Season?
    Zacks16 days ago

    What's in Store for Prothena (PRTA) This Earnings Season?

    Prothena (PRTA) has faced quite a few setbacks in the year so far and hence investors will be focused on management's strategy when it reports first-quarter results next week.

  • Forbes18 days ago

    Flatiron Health, Purchased By Roche, Signs Three-Year Deal With Bristol-Myers

    Flatiron Health was purchased by Roche, the Swiss drug giant, for $1.9 billion in February. At the time, the New York startup said that it would still be open for business with other drug companies. This morning, Flatiron and Bristol-Myers Squibb are announcing a new three-year agreement to use Flatiron’s ability to develop so-called real-world evidence—drug industry jargon for experiments that are not clinical trials but can still provide usable data—to develop Bristol’s experimental cancer drugs.

  • Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
    Zacks23 days ago

    Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat

    Roche (RHHBY) beat sales estimates in the first quarter driven by strong performance of Ocrevus and Perjeta which offset the legacy sales decline.

  • Reuters23 days ago

    BRIEF-Dian Diagnostics In Separate Agreements With Foundation Medicine, F. Hoffmann-La Roche

    April 27 (Reuters) - Dian Diagnostics Group Co Ltd : * SAYS IT SIGNS SEPARATE AGREEMENTS WITH FOUNDATION MEDICINE INC, F. HOFFMANN-LA ROCHE LTD ON TUMOUR TREATMENT Source text in Chinese: https://bit.ly/2FlRDHB ...

  • Reuters24 days ago

    Biosimilar worries takes shine off Roche's guidance hike

    Cheaper copies of Roche's (ROG.S) Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance from new medicines. "The key focus for today looks likely to be the big hit from biosimilars versus the decent performance from Ocrevus and Hemlibra, with the former likely to dominate," Deutsche Bank analyst Tim Race said, calling Rituxan's drop in Europe "stunning". Roche Chief Executive Severin Schwan remained upbeat.

  • Reuters - UK Focus24 days ago

    UPDATE 4-Biosimilar worries takes shine off Roche's guidance hike

    Cheaper copies of Roche's Rituxan toppled the blood cancer drug from its perch as the Swiss company's top seller in the first quarter, unsettling some investors despite a stronger-than-expected performance ...

  • Roche CEO 'Very Confident' on European Sales Growth
    Bloomberg24 days ago

    Roche CEO 'Very Confident' on European Sales Growth

    Severin Schwan, chief executive officer at Roche Holding AG, discusses first-quarter results, the impact of new medicines on European sales and the company's M&A strategy. He speaks with Bloomberg's Nejra ...

  • Reuters - UK Focus24 days ago

    LIVE MARKETS-UK equities fans, please form an orderly queue

    Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market ...

  • The Wall Street Journal24 days ago

    [$$] Roche Raises Outlook After Sales Rise

    AG (ROG.EB) raised its outlook on Thursday after first-quarter sales increased, buoyed by the pharmaceutical company’s multiple-sclerosis drug Ocrevus and its HER2 breast-cancer drugs. Switzerland-based Roche said sales rose to 13.6 billion Swiss francs ($13.8 billion) from CHF12.9 billion, beating expectations. According to a FactSet consensus estimate, Roche was forecast to post sales for CHF13.35 billion.

  • Reuters - UK Focus24 days ago

    LIVE MARKETS-What to watch before the European open

    April 26 - Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts ...

  • Reuters - UK Focus24 days ago

    LIVE MARKETS-Results to watch today: Deutsche Bank, Roche, Kion, Shell

    April 26 - Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts ...

  • Bloomberg24 days ago

    Roche Lifts Forecast as Bet Outside Cancer Starts to Pay Off

    Roche Holding AG’s bet on fields outside cancer is starting to pay off as the Swiss drugmaker boosted its forecast even as sales of one of its top drugs collapsed in Europe.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes